Skip to main content

Advertisement

Table 3 Hazard ratios and 95 % confidence intervals for the association of the epigenetic signature with prostate cancer recurrence

From: Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy

Patients Analysis model Variables Recurrence
HR (95 % CI) P value
All
  Univariate     
   Signature (per 25 % increase) 1.78 (1.48, 2.16) 2.05E−09
  Multivariate     
   Signature (per 25 % increase) 1.48 (1.21, 1.81) 1.38E−04
   Age (per 1-year increase) 0.98 (0.95, 1.01) 0.21
   Gleason score    
    ≤6 1.00   
    7(3 + 4) 2.25 (1.32, 3.48) 2.89E−03
    7(4 + 3) 5.04 (2.64, 9.65) 1.02E−06
    8–10 4.06 (2.00, 8.26) 1.08E−04
   Pathological stagea    
    Local 1.00   
    Regional 2.04 (1.33, 3.14) 1.13E−03
   Diagnostic PSA level (per 1-unit increase) 1.00 (1.00, 1.00) 0.92
Patients with Gleason 7 tumors
  Univariate     
   Signature (per 25 % increase) 1.81 (1.42, 2.31) 1.38E−06
  Multivariate     
   Signature (per 25 % increase) 1.59 (1.24, 2.05) 3.21E−04
   Age (per 1-year increase) 0.99 (0.95, 1.03) 0.56
   Gleason score    
    7(3 + 4) 1.00   
    7(4 + 3) 2.08 (1.18, 3.65) 1.09E−02
   Pathological stagea    
    Local 1.00   
    Regional 1.82 (1.06, 3.11) 2.94E−02
   Diagnostic PSA level (per 1-unit increase) 1.00 (0.99, 1.01) 0.82
Patients with Gleason 7(3 + 4) tumors
  Univariate     
   Signature (per 25 % increase) 1.83 (1.36, 2.45) 5.64E−05
  Multivariate     
   Signature (per 25 % increase) 1.65 (1.21, 2.25) 1.54E−03
   Age (per 1-year increase) 1.00 (0.95, 1.05) 0.86
   Pathological stagea    
    Local 1.00   
    Regional 1.83 (0.97, 3.45) 0.06
   Diagnostic PSA level (per 1-unit increase) 1.00 (0.99, 1.01) 0.80
  1. CI confidence interval, HR hazard ratio, PSA prostate-specific antigen
  2. aLocal stage is pT2, N0/NX, M0. Regional stage is pT3-T4 and/or N1, M0